Literature DB >> 7517208

The N-domain of the biliary glycoprotein (BGP) adhesion molecule mediates homotypic binding: domain interactions and epitope analysis of BGPc.

A M Teixeira1, J Fawcett, D L Simmons, S M Watt.   

Abstract

The biliary glycoproteins (BGPs) represent a group of at least eight differentially spliced molecules belonging to the carcinoembryonic antigen (CEA) subgroup of the CEA family. These molecules are recognized by the CD66 monoclonal antibodies (MoAbs) and function as homotypic and heterotypic adhesion molecules. The extracellular region of the BGPc splice variant comprises an N-terminal IgV-like domain and three IgC2-set domains (A1, B1, and A2). Using soluble recombinant BGP domain variants, we demonstrate in this report that the N-terminal domain mediates homotypic adhesion. Furthermore, this adhesion is both temperature- and cation-dependent. The soluble domain variants of BGP are ideal molecules for epitope mapping. Using these constructs, we have mapped 11 MoAbs that react with the CEA family to different domains of BGPc and have shown that the CD66 MoAbs, YTH71.3.2 and CLBgran 10 (M38), recognize epitopes in the N-terminal domain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517208

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner.

Authors:  Elizabeth O Lobo; Zhifang Zhang; John E Shively
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

Review 2.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Differential recognition of members of the carcinoembryonic antigen family by Opa variants of Neisseria gonorrhoeae.

Authors:  M P Bos; F Grunert; R J Belland
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  Soluble isoforms of CEACAM1 containing the A2 domain: increased serum levels in patients with obstructive jaundice and differences in 3-fucosyl-N-acetyl-lactosamine moiety.

Authors:  L Dráberová; H Cerná; H Brodská; M Boubelík; S M Watt; C P Stanners; P Dráber
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

5.  Role of calpain-9 and PKC-delta in the apoptotic mechanism of lumen formation in CEACAM1 transfected breast epithelial cells.

Authors:  Charng-Jui Chen; Tung Nguyen; John E Shively
Journal:  Exp Cell Res       Date:  2009-11-10       Impact factor: 3.905

6.  CEACAM1-4S, a cell-cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture.

Authors:  Julia Kirshner; Charng-Jui Chen; Pingfang Liu; Jie Huang; John E Shively
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-09       Impact factor: 11.205

7.  Mutational analysis of human CEACAM1: the potential of receptor polymorphism in increasing host susceptibility to bacterial infection.

Authors:  Silvia Villullas; Darryl J Hill; Richard B Sessions; Jon Rea; Mumtaz Virji
Journal:  Cell Microbiol       Date:  2006-08-31       Impact factor: 3.715

Review 8.  Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.

Authors:  Gianfranco Pittari; Luca Vago; Moreno Festuccia; Chiara Bonini; Deena Mudawi; Luisa Giaccone; Benedetto Bruno
Journal:  Front Immunol       Date:  2017-11-07       Impact factor: 7.561

9.  Interdependency of CEACAM-1, -3, -6, and -8 induced human neutrophil adhesion to endothelial cells.

Authors:  Keith M Skubitz; Amy P N Skubitz
Journal:  J Transl Med       Date:  2008-12-10       Impact factor: 5.531

Review 10.  Signaling by epithelial members of the CEACAM family - mucosal docking sites for pathogenic bacteria.

Authors:  Arnaud Kengmo Tchoupa; Tamara Schuhmacher; Christof R Hauck
Journal:  Cell Commun Signal       Date:  2014-04-15       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.